Adolescents with acute lymphoblastic leukemia (ALL) represent an understudied subset of the patient population. Adolescents 16 to 21 years of age are eligible for entry onto both children and adult cooperative group trials. However, the rate of participation of adolescents in ALL trials is quite low. Pediatric and adult trials often deliver substantially different therapy. Because adolescents have worse event-free survival rates than younger children with ALL, specific studies aimed at improving outcomes for adolescents are critical for helping this understudied patient population. Researchers at the University of Chicago Children?s Hospital led a clinical trial which included adolescents and young adults to determine the effects of intensification of chemotherapy on treatment outcomes, stratifying patients based on early marrow response to chemotherapy.
Go to Previous Page
Go to Next Page